AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more
AptaBio Therapeutics Inc (293780) - Net Assets
Latest net assets as of September 2025: ₩44.61 Billion KRW
Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has net assets worth ₩44.61 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩67.12 Billion) and total liabilities (₩22.51 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩44.61 Billion |
| % of Total Assets | 66.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -24.77% |
| 10-Year Change | N/A |
| Growth Volatility | 118.3 |
AptaBio Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how AptaBio Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AptaBio Therapeutics Inc (2017–2024)
The table below shows the annual net assets of AptaBio Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩54.20 Billion | -11.68% |
| 2023-12-31 | ₩61.36 Billion | +17.17% |
| 2022-12-31 | ₩52.37 Billion | -15.07% |
| 2021-12-31 | ₩61.67 Billion | -14.40% |
| 2020-12-31 | ₩72.04 Billion | -4.14% |
| 2019-12-31 | ₩75.16 Billion | +310.42% |
| 2018-12-31 | ₩18.31 Billion | +158.06% |
| 2017-12-31 | ₩-31.54 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to AptaBio Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7824782832000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩164.31 Billion | 303.17% |
| Total Equity | ₩54.20 Billion | 100.00% |
AptaBio Therapeutics Inc Competitors by Market Cap
The table below lists competitors of AptaBio Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hanover Bancorp Inc
NASDAQ:HNVR
|
$88.31 Million |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
$88.31 Million |
|
PDS Limited
NSE:PDSL
|
$88.36 Million |
|
Cogelec SA
PA:ALLEC
|
$88.37 Million |
|
Caravel Minerals Ltd
AU:CVV
|
$88.26 Million |
|
Nordhealth AS
OL:NORDH
|
$88.25 Million |
|
LuxUrban Hotels Inc. 13.00% Series A Cumulative Redeemable Preferred Stock
NASDAQ:LUXHP
|
$88.24 Million |
|
NAFCO CO. LTD.
F:64E
|
$88.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AptaBio Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 61,363,391,270 to 54,197,061,000, a change of -7,166,330,270 (-11.7%).
- Net loss of 29,377,949,530 reduced equity.
- Other factors increased equity by 22,211,619,260.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-29.38 Billion | -54.21% |
| Other Changes | ₩22.21 Billion | +40.98% |
| Total Change | ₩- | -11.68% |
Book Value vs Market Value Analysis
This analysis compares AptaBio Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩-3488.75 | ₩6930.00 | x |
| 2018-12-31 | ₩1056.23 | ₩6930.00 | x |
| 2019-12-31 | ₩3453.27 | ₩6930.00 | x |
| 2020-12-31 | ₩3246.45 | ₩6930.00 | x |
| 2021-12-31 | ₩2778.15 | ₩6930.00 | x |
| 2022-12-31 | ₩2348.53 | ₩6930.00 | x |
| 2023-12-31 | ₩2751.86 | ₩6930.00 | x |
| 2024-12-31 | ₩2016.16 | ₩6930.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AptaBio Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -874.09%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.43x
- Recent ROE (-54.21%) is below the historical average (-18.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -10372.02% | 0.03x | 0.00x | ₩-27.97 Billion |
| 2018 | -22.19% | -279.42% | 0.07x | 1.11x | ₩-5.89 Billion |
| 2019 | -8.38% | -618.31% | 0.01x | 1.03x | ₩-13.81 Billion |
| 2020 | -5.44% | -1149.08% | 0.00x | 1.05x | ₩-11.12 Billion |
| 2021 | -17.33% | -4778.80% | 0.00x | 1.05x | ₩-16.86 Billion |
| 2022 | -20.17% | -21849.25% | 0.00x | 1.07x | ₩-15.80 Billion |
| 2023 | -19.66% | -3724.24% | 0.00x | 1.51x | ₩-18.20 Billion |
| 2024 | -54.21% | -874.09% | 0.04x | 1.43x | ₩-34.80 Billion |
Industry Comparison
This section compares AptaBio Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $472,965,132,317
- Average return on equity (ROE) among peers: 3.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AptaBio Therapeutics Inc (293780) | ₩44.61 Billion | 0.00% | 0.50x | $88.30 Million |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $76.07 Million |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $3.71 Billion |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $29.69 Million |
| Ildong Holdings Co Ltd (000230) | $310.17 Billion | 8.80% | 0.65x | $48.77 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $103.58 Million |
| Donga Socio Holdings (000640) | $1.03 Trillion | 5.64% | 0.91x | $204.37 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $278.79 Million |
| JW Pharmaceutical Corp (001065) | $276.31 Billion | -3.96% | 1.36x | $246.19 Million |
| Samsung Pharm (001360) | $46.24 Billion | -2.15% | 1.82x | $64.85 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $165.68 Billion | 10.17% | 0.83x | $27.46 Million |